TRAPPC2L
Basic information
Region (hg38): 16:88856220-88862686
Links
Phenotypes
GenCC
Source:
- encephalopathy, progressive, early-onset, with episodic rhabdomyolysis (Limited), mode of inheritance: AR
- encephalopathy, progressive, early-onset, with episodic rhabdomyolysis (Limited), mode of inheritance: AR
- encephalopathy, progressive, early-onset, with episodic rhabdomyolysis (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Encephalopathy, progressive, early-onset, with episodic rhabdomyolysis | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Musculoskeletal; Neurologic | 30120216 |
ClinVar
This is a list of variants' phenotypes submitted to
- Mucopolysaccharidosis, MPS-IV-A (11 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TRAPPC2L gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 14 | 17 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 2 | 1 | 3 | |||
non coding | 11 | 33 | 45 | 103 | ||
Total | 11 | 7 | 47 | 46 | 11 |
Highest pathogenic variant AF is 0.00000669
Variants in TRAPPC2L
This is a list of pathogenic ClinVar variants found in the TRAPPC2L region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-88856269-G-A | Likely benign (May 01, 2021) | |||
16-88856712-T-G | Benign (Aug 19, 2020) | |||
16-88856728-GCCCTGCCCCGT-G | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Nov 28, 2023) | ||
16-88856738-G-A | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Apr 03, 2023) | ||
16-88856739-T-G | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Oct 03, 2023) | ||
16-88856744-C-T | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Jan 18, 2024) | ||
16-88856745-C-A | Mucopolysaccharidosis, MPS-IV-A | Likely benign (May 09, 2023) | ||
16-88856745-C-G | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Oct 05, 2023) | ||
16-88856745-C-T | Mucopolysaccharidosis, MPS-IV-A | Benign (Jan 19, 2024) | ||
16-88856746-G-A | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Nov 13, 2023) | ||
16-88856746-G-C | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Apr 30, 2023) | ||
16-88856749-C-A | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Sep 03, 2023) | ||
16-88856750-G-C | Mucopolysaccharidosis, MPS-IV-A | Likely benign (Jan 31, 2024) | ||
16-88856754-T-C | Mucopolysaccharidosis, MPS-IV-A | Uncertain significance (Sep 07, 2023) | ||
16-88856757-C-G | Mucopolysaccharidosis, MPS-IV-A | Pathogenic (Mar 21, 2023) | ||
16-88856757-C-T | Mucopolysaccharidosis, MPS-IV-A | Pathogenic (May 02, 2023) | ||
16-88856759-T-C | Mucopolysaccharidosis, MPS-IV-A | Uncertain significance (Feb 01, 2021) | ||
16-88856760-C-A | Mucopolysaccharidosis, MPS-IV-A | Uncertain significance (Jul 26, 2022) | ||
16-88856760-C-G | Mucopolysaccharidosis, MPS-IV-A | Pathogenic (Aug 31, 2021) | ||
16-88856760-C-T | Mucopolysaccharidosis, MPS-IV-A | Conflicting classifications of pathogenicity (Jan 24, 2023) | ||
16-88856761-GTC-G | Mucopolysaccharidosis, MPS-IV-A | Pathogenic (Jul 30, 2021) | ||
16-88856762-T-C | Mucopolysaccharidosis, MPS-IV-A | Pathogenic/Likely pathogenic (Feb 14, 2023) | ||
16-88856763-C-A | Mucopolysaccharidosis, MPS-IV-A • not specified | Uncertain significance (Sep 27, 2024) | ||
16-88856765-A-C | Uncertain significance (Mar 01, 2019) | |||
16-88856766-T-G | Mucopolysaccharidosis, MPS-IV-A | Uncertain significance (Aug 12, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TRAPPC2L | protein_coding | protein_coding | ENST00000301021 | 5 | 6467 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.68e-11 | 0.00703 | 125701 | 0 | 43 | 125744 | 0.000171 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.384 | 102 | 91.7 | 1.11 | 0.00000565 | 925 |
Missense in Polyphen | 25 | 26.892 | 0.92963 | 335 | ||
Synonymous | -2.20 | 56 | 38.6 | 1.45 | 0.00000278 | 255 |
Loss of Function | -1.69 | 13 | 7.89 | 1.65 | 5.00e-7 | 80 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000335 | 0.000308 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000326 | 0.000326 |
Finnish | 0.000464 | 0.000462 |
European (Non-Finnish) | 0.000182 | 0.000176 |
Middle Eastern | 0.000326 | 0.000326 |
South Asian | 0.0000745 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: May play a role in vesicular transport from endoplasmic reticulum to Golgi. {ECO:0000269|PubMed:19416478}.;
- Pathway
- Vesicle-mediated transport;Membrane Trafficking;Post-translational protein modification;Metabolism of proteins;Transport to the Golgi and subsequent modification;Asparagine N-linked glycosylation;Rab regulation of trafficking;RAB GEFs exchange GTP for GDP on RABs;COPII-mediated vesicle transport;ER to Golgi Anterograde Transport
(Consensus)
Recessive Scores
- pRec
- 0.113
Intolerance Scores
- loftool
- 0.384
- rvis_EVS
- -0.12
- rvis_percentile_EVS
- 44.89
Haploinsufficiency Scores
- pHI
- 0.168
- hipred
- N
- hipred_score
- 0.197
- ghis
- 0.573
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.974
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Trappc2l
- Phenotype
Gene ontology
- Biological process
- endoplasmic reticulum to Golgi vesicle-mediated transport;COPII vesicle coating;protein complex oligomerization
- Cellular component
- Golgi membrane;endoplasmic reticulum;cytosol;TRAPP complex;intracellular membrane-bounded organelle;perinuclear region of cytoplasm
- Molecular function
- protein binding;Rab guanyl-nucleotide exchange factor activity